Matthew Smith, M.D., Ph.D. is the Director of the Genitourinary Malignancies Program at the Massachusetts General Hospital Cancer Center. His clinical practice and research program focus on the management of prostate cancer.
- Centers & Specialties
- Clinical Interests
- Prostate cancer
- Medical Education
- MD, Duke University School of Medicine
- PhD, Duke University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
- Board Certifications
- Medical Oncology
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- BMC HealthNet Mass Health MCO/ACO
- Cigna (PAL #'s)
- Commonwealth Care Alliance
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Railroad Medicare
- Railroad Medicare - ACD
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
- Well Sense Pediatrics
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Provider Gender
He is an internationally recognized expert in prostate cancer. He has published extensively on treatment and prevention of bone metastases and prostate cancer survivorship. He has authored more than 150 peer-reviewed articles including manuscripts in New England Journal of Medicine, Journal of Clinical Oncology, Cancer, Journal of Clinical Endocrinology and Metabolism, and Clinical Cancer Research. His research is supported by competitive grants and awards from the National Institutes of Health, Lance Armstrong Foundation Research Award, and the Prostate Cancer Foundation.
- Research Summary
- Dr. Smith leads a clinical research program in prostate cancer focused on cancer survivorship, treatment and prevention of bone metastases, and novel therapeutics. With a multidisciplinary research team, he identified previously unrecognized adverse effects of androgen deprivation therapy including osteoporosis, sarcopenia, obesity, lipid alterations, insulin resistance, and greater risks for fractures, diabetes, and cardiovascular disease. These novel observations have provided fundamental insights in the management of prostate cancer and informed the design of global clinical trials to prevent treatment-related morbidity in prostate cancer survivors. His research has contributed to the approval of new drugs to prevent skeletal morbidity in men with prostate cancer. He leads international studies to prevent and treat bone metastases. He leads an active clinical research program in novel therapy for prostate cancer. His research program is supported by principal investigator peer-reviewed research funding from federal, investigator-initiated industry, and foundation grants including an NIH K24 mid-career investigator award and a Prostate Cancer Foundation Transformational grant. He has authored more than 70 original research reports and more than 80 reviews and book chapters on prostate cancer.
A clinical trial led by investigators at Massachusetts General Hospital and University of California, San Francisco found that treatment with an investigational androgen receptor inhibitor significantly delayed the development of metastasis in patients with prostate cancer that had become resistant to standard androgen-deprivation therapy.
An international clinical trial has found that treatment with a drug that suppresses the normal breakdown of bone can delay the development of bone metastases in men with prostate cancer.
Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, led a study on a new targeted therapy to stop bone loss, increase bone density and prevent spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
55 Fruit Street
Boston, MA 02114